secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001213900-26-015795
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vyome reports positive Phase 2 data for VT-1953 in malignant fungating wounds; primary endpoint met
--------------------------------------------------------------------------------

- VT-1953 achieved significant reduction in malodor at Day 14 (p=0.002 vs baseline; p=0.0015 vs vehicle).
- Secondary endpoint met: patient-reported impact of malodor on QoL improved significantly (p=0.0256 vs vehicle).
- Exploratory endpoints showed significant pain reduction (p=0.002) and improved composite QoL at Day 14.
- No treatment-emergent adverse events or safety signals reported across the 15-patient study.
- Company filed for orphan drug designation and plans to discuss Phase 3 design with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000121390026015795/0001213900-26-015795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000121390026015795/ea0276975-8k_vyome.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-015795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer